



Grifols launches new 2000 FVIII IU ALPHANATE® (Antihemophilic Factor/von Willebrand Factor Complex [Human]) assay

RESEARCH TRIANGLE PARK, NC, USA, September 19, 2014 /EINPresswire.com/ -- Grifols, a leader in the production of plasma-derived medicines, announces the launch of a 2000 IU/vial assay size for ALPHANATE. ALPHANATE is indicated for the control and prevention of bleeding in patients with Hemophilia A and for surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery.

With the launch of the new 2000 IU FVIII ALPHANATE assay, Grifols will now supply the largest FVIII and von Willebrand Factor:Ristocetin Cofactor (VWF:RCO) assay available on the market for any plasma-derived FVIII concentrate. The higher potency allows patients who previously used a 1500 IU assay to reduce their potential total administration time by 30% every day.

“This higher potency offers a significant advantage to Hemophilia A patients that require high dose therapy,” said Joel Abelson, President of North American Commercial Operations. “Since the approval of the 2000 IU FVIII assay, ALPHANATE has twice the factor and half the volume of any other FVIII/VWF complex product. The larger assay may help patients decrease their overall infusion time and will reduce the total volume needed for a high dose infusion.”

The 2000 IU FVIII ALPHANATE assay will be available October 1, 2014.

For more information about ALPHANATE, please [click here](#).

About Grifols

Grifols is a global healthcare company with a 70-year legacy of improving people's health and well being through the development of life-saving plasma medicines, diagnostics systems, and hospital pharmacy products

The company is present in more than 100 countries worldwide and is headquartered in Barcelona, Spain. Grifols is a leader in plasma collection with a network of 150 plasma donor centers in the U.S., and a leading producer of plasma-derived biological medicines. The company also provides a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks and transfusion centers, and is a recognized leader in transfusion medicine.

In 2013, sales exceeded 2,740 million euros with a headcount of 13,200 employees. Grifols demonstrates its commitment to advancing healthcare by allocating a significant portion of its annual income to R&D.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information on Grifols and its facilities, please visit www.grifols.com.

Rebecca Barnes
Grifols
9193166590
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.